for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lonza Group AG

LONN.S

Latest Trade

397.80CHF

Change

-2.20(-0.55%)

Volume

569,407

Today's Range

397.20

 - 

401.10

52 Week Range

253.50

 - 

401.90

As of on the Virt-X ∙ Minimum 15 minute delay

Pricing

Previous Close
400.00
Open
399.30
Volume
569,407
3M AVG Volume
7.10
Today's High
401.10
Today's Low
397.20
52 Week High
401.90
52 Week Low
253.50
Shares Out (MIL)
74.02
Market Cap (MIL)
29,787.50
Forward P/E
--
Dividend (Yield %)
0.34

Next Event

Lonza Group AG at Bank of America Merrill Lynch CEO Roadshow - Boston & New York

Latest Developments

More

Lonza Chairman Says Says No Rush To Make Decision On Specialty Chemicals Business

Lonza Announces Price Increases For Some Ammonium Products

Lonza Says Ibex Solutions To Support Genmab Clinical Portfolio

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lonza Group AG

Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.

Contact Info

Muenchensteinerstrasse 38

+41.61.3168111

https://www.lonza.com/

Executive Leadership

Albert M. Baehny

Independent Chairman of the Board

Patrick Aebischer

Independent Vice-Chairman of the Board of Directors

Rodolfo Savitzky

Chief Financial Officer, Member of the Executive Committee

Sven Abend

Chief Operating Officer - Specialty Ingredients, Member of the Management Board, Chief Strategy Officer

Fridtjof Helemann

Chief Human Resource Officer, Member of the Executive Committee

Key Stats

2.17 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, CHF)

2017

5.1K

2018

5.5K

2019

5.9K

2020(E)

6.3K
EPS (CHF)

2017

11.740

2018

11.980

2019

13.590

2020(E)

13.826
Price To Earnings (TTM)
39.14
Price To Sales (TTM)
5.03
Price To Book (MRQ)
4.56
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
54.51
LT Debt To Equity (MRQ)
43.10
Return on Investment (TTM)
6.75
Return on Equity (TTM)
5.50

Latest News

Latest News

BRIEF-Lonza Chairman Says Says No Rush To Make Decision On Specialty Chemicals Business

* LONZA CHAIRMAN SAYS LONG-TERM STRATEGIC FOCUS IS ON BIOTECH, DRUG AND NUTRITION BUSINESS, OPTIONS FOR SPECIALTY CHEMICALS INCLUDE SALE, SPINOFF, IPO OR KEEP IN PORTFOLIO

BRIEF-Lonza Announces Price Increases For Some Ammonium Products

* LONZA ANNOUNCES PRICE INCREASES FOR SELECTED PRODUCTS IN ITS QUATS, AMINES AND AMINE OXIDES PORTFOLIOS GLOBALLY

BRIEF-Lonza Says Ibex Solutions To Support Genmab Clinical Portfolio

* SAYS IBEX SOLUTIONS TO SUPPORT GENMAB’S GROWING CLINICAL PORTFOLIO

BRIEF-Celltrion and Lonza sign contract to make Remsima drug substance

* CELLTRION AND LONZA SIGN CONTRACT TO MANUFACTURE REMSIMA DRUG SUBSTANCE

Lonza first-half profit plunges, says on track to hit full-year goals

Lonza Group's <LONN.S> first-half profit plunged as it took losses linked to the sale of its water business and as difficulties at its specialty ingredients business continued, though the Swiss drug ingredients maker confirmed full-year targets.

BRIEF-Lonza Expands Bioconjugation Facility

* LONZA EXPANDS BIOCONJUGATION FACILITY AND ANNOUNCES APPROVAL OF THIRD COMMERCIAL ADC

Lonza says on track to hit full-year 2019 targets

Swiss drug ingredients maker Lonza Group said on Wednesday it is on pace to hit its 2019 goal of mid-to-high single-digit sales growth as double-digit gains in its drug and biotech unit in the first half offset weaker business elsewhere.

Lonza fills portfolio hole by buying Novartis drug bottling plant

Lonza Group is buying a drug bottling plant from Novartis in northern Switzerland as the Swiss drug ingredients maker fills a gap in its offering for drugmakers seeking to outsource production.

Lonza snaps up Novartis fill-and-finish facility to expand offering

Lonza Group is buying a sterile fill-and-finish facility from Novartis as the Swiss drug ingredients maker boosts its offering for pharmaceuticals companies.

Lonza carves out Specialty Ingredients business, shares rise

Lonza Group will carve out its Specialty Ingredients (LSI) business and cut around 130 jobs there as it reorganizes a division that has struggled, the Swiss group said on Monday.

BRIEF-Carve-out costs for Lonza Specialty Ingredients Won't Affect 2019 Guideline - CEO

* LONZA GROUP CEO SAYS ADDITIONAL COSTS FOR CARVED-OUT SPECIALTY INGREDIENTS BUSINESS WON'T AFFECT 2019 GUIDELINES Source text for Eikon: Further company coverage: (Reporting By Michael Shields)

REFILE-Lonza to carve out Specialty Ingredients business

Lonza Group will carve out its Specialty Ingredients (LSI) business and cut around 130 jobs there, as it reorganises a division that has struggled this year.

BRIEF-Lonza Group Announced Intention To Proceed With A Carve-Out Of Its Specialty Ingredients Segment (LSI)

* LONZA GROUP AG - INTENTION TO PROCEED WITH A CARVE-OUT OF ITS SPECIALTY INGREDIENTS SEGMENT (LSI)

BRIEF-Lonza says newly aligned specialty ingredients segment performed below expectations in Q1

* OUTLOOK 2019 MAINTAINED AND ACCELERATED PORTFOLIO REVIEW ONGOING

BRIEF-Lonza Group And Chr. Hansen To Establish Joint Venture

* LONZA AND CHR. HANSEN IN JOINT VENTURE TO ACCELERATE MOMENTUM IN MICROBIOME

BRIEF-Lonza Completes Divestment Of Water Care Business

* ANNOUNCED TODAY COMPLETION OF DIVESTMENT OF ITS FORMER WATER CARE BUSINESS AND OPERATIONS TO PLATINUM EQUITY FOR USD 630 MILLION Source text for Eikon: Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-Lonza Aligns Structure, Creates New Executive Committee Position

* LONZA STRENGTHENS PHARMA, BIOTECH AND NUTRITION OFFERINGS WITH ALIGNED STRUCTURE AND NEW EXECUTIVE COMMITTEE APPOINTMENT

BRIEF-Emerald, Lonza To Manufacture Cannabinoid-Derived Drug Candidate

* EMERALD HEALTH PHARMACEUTICALS AND LONZA ANNOUNCE AGREEMENT FOR MANUFACTURING OF NOVEL CANNABINOID-DERIVED DRUG CANDIDATE

BRIEF-Lonza And Allcells Collaborate On Hematopoietic Primary Cells

* LONZA AND ALLCELLS JOIN FORCES FOR GLOBAL COMMERCIALIZATION OF HEMATOPOIETIC PRIMARY CELLS Source text: https://bit.ly/2GbE1ne Further company coverage: (Reporting by Berlin Speed Desk)

BRIEF-Lonza CEO said he requested fast handover to successor

* LONZA CEO RIDINGER SAYS CHANGE TO INTERNAL SUCCESSOR RIGHT MOVE, IMPORTANT TO HAVE FAST HANDOVER

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up